Eisman MS[au] - Search Results

Year	Number of Results
1992	2
1994	1
1995	1
1997	1
1999	1
2011	1
2016	1
2024	0

1

Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clustering.

Gu C, Lamb ML, Johannes JW, Sylvester MA, Eisman MS, Harrison RA, Hu H, Kazmirski S, Mikule K, Peng B, Su N, Wang W, Ye Q, Zheng X, Lyne PD, Scott DA. Gu C, et al. Among authors: eisman ms. Bioorg Med Chem Lett. 2016 Oct 1;26(19):4775-4780. doi: 10.1016/j.bmcl.2016.08.030. Epub 2016 Aug 12. Bioorg Med Chem Lett. 2016. PMID: 27578247

2

Efficacy of AR-R15896AR in the rat monofilament model of transient middle cerebral artery occlusion.

Bialobok P, Cregan EF, Sydserff SG, Eisman MS, Miller JA, Cross AJ, Simmons R, Gendron P, McCarthy DJ, Palmer GC. Bialobok P, et al. Among authors: eisman ms. J Stroke Cerebrovasc Dis. 1999 Nov-Dec;8(6):388-97. doi: 10.1016/s1052-3057(99)80046-9. J Stroke Cerebrovasc Dis. 1999. PMID: 17895192

3

Ultra-low exposure to α-7 nicotinic acetylcholine receptor partial agonists elicits an improvement in cognition that corresponds with an increase in α-7 receptor expression in rodents: implications for low dose clinical efficacy.

Werkheiser JL, Sydserff S, Hubbs SJ, Ding M, Eisman MS, Perry D, Williams AJ, Smith JS, Mrzljak L, Maier DL. Werkheiser JL, et al. Among authors: eisman ms. Neuroscience. 2011 Jul 14;186:76-87. doi: 10.1016/j.neuroscience.2011.04.033. Epub 2011 Apr 24. Neuroscience. 2011. PMID: 21550383

4

-(S)-Alpha-phenyl-2-pyridine-ethanamine Dihydrochloride-, a low affinity uncompetitive N-methyl-D-aspartic acid antagonist, is effective in rodent models of global and focal ischemia.

Cregan EF, Peeling J, Corbett D, Buchan AM, Saunders J, Auer RN, Gao M, Mccarthy DJ, Eisman MS, Campbell TM, Murray RJ, Stagnitto ML, Palmer GC. Cregan EF, et al. Among authors: eisman ms. J Pharmacol Exp Ther. 1997 Dec;283(3):1412-24. J Pharmacol Exp Ther. 1997. PMID: 9400017

5

Brain uptake and biotransformation of remacemide hydrochloride, a novel anticonvulsant.

Heyn H, McCarthy DJ, Curry SH, Eisman MS, Anders MW. Heyn H, et al. Among authors: eisman ms. Drug Metab Dispos. 1994 May-Jun;22(3):443-6. Drug Metab Dispos. 1994. PMID: 8070322

6

Biological profile of the metabolites and potential metabolites of the anticonvulsant remacemide.

Palmer GC, Murray RJ, Wilson TC, Eisman MS, Ray RK, Griffith RC, Napier JJ, Fedorchuk M, Stagnitto ML, Garske GE. Palmer GC, et al. Among authors: eisman ms. Epilepsy Res. 1992 Jun;12(1):9-20. doi: 10.1016/0920-1211(92)90086-9. Epilepsy Res. 1992. PMID: 1388119

7

Quantitation of the novel anticonvulsant remacemide in rat and dog plasma and urine: application of the plasma methodology to measure the plasma protein binding of remacemide.

Wilson TC, Eisman MS, Machulskis GE. Wilson TC, et al. Among authors: eisman ms. J Chromatogr. 1992 Nov 6;582(1-2):195-202. doi: 10.1016/0378-4347(92)80319-l. J Chromatogr. 1992. PMID: 1491041

8

Disposition and pharmacokinetics of remacemide hydrochloride in male Sprague-Dawley rats.

Curry S, McCarthy DJ, Case KR, Eisman MS, Marler MR, Mahmood NA. Curry S, et al. Among authors: eisman ms. Ann N Y Acad Sci. 1995 Sep 15;765:330-1. doi: 10.1111/j.1749-6632.1995.tb16606.x. Ann N Y Acad Sci. 1995. PMID: 7486635 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

8 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year